Guardian Capital Advisors (Canada)’s AbbVie ABBV Stock Holding History

Guardian Capital Advisors (Canada)’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,440	Closed	-$219K	–	155
2022 Q4	$219K	Sell	1,440 -340	-19%	-$52.1K	0.02%	149
2022 Q3	$249K	Hold	1,780	–	–	0.03%	139
2022 Q2	$268K	Hold	1,780	–	–	0.03%	145
2022 Q1	$298K	Buy	+1,780	New	+$259K	0.03%	145
2019 Q1	–	Sell	-2,600	Closed	-$220K	–	157
2018 Q4	$220K	Buy	+2,600	New	+$229K	0.03%	142
2015 Q4	–	Sell	-4,025	Closed	-$214K	–	171
2015 Q3	$214K	Buy	+4,025	New	+$262K	0.04%	156

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Guardian Capital Advisors (Canada)'s ABBV Position: Q1 2023 in Review

Guardian Capital Advisors (Canada) sold out of AbbVie (ABBV) in Q1 2023, closing a stake of 1,440 shares — an estimated $219K sold.

Guardian Capital Advisors (Canada) first reported a position in ABBV in Q3 2015 and held it in 6 quarters. The position peaked at $298K in Q1 2022. 3,138 funds tracked by Wall St. Rank hold ABBV as of Q1 2023.

Guardian Capital Advisors (Canada) reported no remaining AbbVie position as of Q1 2023 after selling out during the quarter.
Guardian Capital Advisors (Canada) sold 1,440 AbbVie shares in Q1 2023, an estimated $219K.
Guardian Capital Advisors (Canada) first reported a position in AbbVie in Q3 2015 and held it in 6 quarters.
Guardian Capital Advisors (Canada)'s AbbVie position peaked at $298K in Q1 2022.
3,138 funds tracked by Wall St. Rank held AbbVie as of Q1 2023.

Based on Guardian Capital Advisors (Canada)'s 13F filing for Q1 2023, filed 15 May 2023.